ReviewArchives of medical science : AMS2016
Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
Review in Archives of medical science : AMS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04558125 (Low-Dose Tenecteplase in Covid-19 Patients With Acute Pulmonary Embolism), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Low-Dose Tenecteplase in Covid-19 Patients With Acute Pulmonary Embolism: A Randomized, Double-Blind, Placebo-Controlled Trial
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Tenecteplase in Pulmonary Embolism Patients: A Meta-Analysis and Systematic Review.Frontiers in medicine · 2022Pooled it
- Safety assessment of tenecteplase for the treatment of acute myocardial infarction and ischemic stroke, and identification of key genes.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Core determinant of theFrontiers in pharmacology · 2026Article
- Split NeissLock with Spy-Acceleration Arms Mammalian Proteins for Anhydride-Mediated Cell Ligation.ACS chemical biology · 2025Article
- Review
- Article
- Risk Stratification in Patients with Acute Pulmonary Embolism: Current Evidence and Perspectives.Journal of clinical medicine · 2022Review
- Recombinant Destabilase fromCurrent issues in molecular biology · 2021Article
- Acute Reperfusion Therapies for Acute Ischemic Stroke.Journal of clinical medicine · 2021Review
- COVID-19 pandemic: Challenges and solutions from the cardiology pharmacist's perspective.Journal of the American College of Clinical Pharmacy : JACCP · 2020Article
- Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?The western journal of emergency medicine · 2020Review
- A new era for stroke therapy: Integrating neurovascular protection with optimal reperfusion.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018Review
- Clinical chameleons: an emergency medicine focused review of carbon monoxide poisoning.Internal and emergency medicine · 2018Review
- Review
- Thrombolysis in STEMI in the era of COVID - Holding fort in cardiologist deficit locales.Indian heart journalObservational
- The evaluation of Tenecteplase for the treatment of ischemic stroke (real-world data).Frontiers in neurologyArticle
- Is Tenecteplase a Viable Alternative to Alteplase in the Treatment of Acute Ischemic Stroke?Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlteplase and tenecteplase are two widely used thrombolytic agents and are both approved for the treatment of acute myocardial infarction. These two molecules have increased fibrin specificity compared with older thrombolytics but distinct pharmacokinetic properties and may differ in terms of risks and benefits. We decided to review the available evidence comparing the safety and efficacy of these two molecules in acute coronary syndrome (ACS) or pulmonary embolism (PE). MATERIAL AND
methodsTo compare the efficacy and safety profile of alteplase and tenecteplase, we systematically searched PubMed, Cochrane and Embase for randomized studies comparing weight-adjusted alteplase to weight-adjusted tenecteplase in patients with ACS or PE. The primary endpoint was the risk of major bleeding, and secondary endpoints were risk of intracranial haemorrhage (ICH), vessel recanalization and 30-day mortality.
resultsThree studies including 17,325 patients with ACS were included in a quantitative meta-analysis. No study compared alteplase to tenecteplase in acute PE. Tenecteplase was associated with a statistically significant reduction of the risk of major bleeding compared to alteplase (RR = 0.79; 95% CI: 0.69-0.90,
conclusionsThe available evidence suggests that tenecteplase is associated with a reduced risk of major bleeding compared to alteplase in ACS without evidence of reduced efficacy. These results are however mainly dependent on a single study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.